Coronavirus in Mexico: 5,920 infections and 171 deaths in the last 24 hours from COVID-19
On Monday, July 26th, the Ministry of Health (SSa) released the most important data on the coronavirus epidemic in Mexico. Through a daily technical communiqué, it informed that 171 deaths and 5,920 new cases of COVID-19 were registered in the country. According to the demographic data of the epidemic, confirmed cases show a predominance of men, with 50.1 percent. The overall median age is 42 years.
With these figures, 2,754,438 infections and 238,595 deaths caused by the SARS-CoV-2 virus have been accumulated nationwide. In addition, 458,871 suspected cases were reported, 5,003,743 negative cases, 101,630 estimated active cases, and 8,217,052 people studied since the beginning of the sanitary contingency.
By place of residence, Mexico City (760,440), State of Mexico (282,067), Nuevo Leon (137,495), Guanajuato (136,803), Jalisco (100,190), Puebla (89,494), Sonora (86,228), Tabasco (84,997), Veracruz (76,211) and Queretaro (72,905) are the states with the highest number of accumulated infections, with 66% of the total.
Regarding people who presented symptoms of coronavirus in the last 14 days, Mexico City also occupies the first place, with 31,214 active cases, followed by the State of Mexico, with 9,875; Jalisco, with 5,459; Nuevo Leon, with 5,018; Veracruz, with 4,120; Sinaloa, with 3,437; Quintana Roo, with 3,140; Tabasco, with 2,868; and Guerrero, with 2,539.
On the other hand, it is estimated that there are 2,947,554 infections of the disease in Mexico. In addition, there are 12,275 suspected deaths and 2,160,130 recovered patients. Regarding the distribution by sex and age of the deaths caused by COVID-19, 62% of the deaths were male. The average age of coronavirus deaths was 64 years.
Mexico City leads with 45,437 deaths, followed by the State of Mexico (28,491), Jalisco (12,833), Puebla (12,489), Guanajuato (11,094), Veracruz (10,279), Nuevo Leon (10,094), Baja California (8,777), Chihuahua (7,634) and Sonora (7,020). The aforementioned entities together represent more than half (64.6%) of all deaths in the country.
Worldwide, confirmed COVID-19 infections as of July 26th totaled 194,080,019. In addition, the global case fatality rate stood at 2.1%, as the coronavirus pandemic has caused the death of 4,162,304 people worldwide.
Epidemiological and Clinical Impact of COVID-19
In December 2019, a series of cases of pneumonia of unknown cause emerged in Wuhan, Hubei, China, with clinical presentations closely resembling viral pneumonia. On January 7, 2020, the etiologic agent responsible for this picture was identified as a new betacoronavirus (SARS-CoV-2), distinct from SARS-CoV (2003) and MERS-CoV (2012), the disease is referred to as COVID-19; undoubtedly this new virus is the first pandemic of the 21st century that has come to permanently alter and transform the daily, economic, political and social life of the world. The disease spread to the countries of the region: Thailand, Hong Kong, South Korea, Japan and later to Iran, Italy, Spain, and the rest of Europe; in America, it appeared initially in the state of Washington and with greater intensity in New York and in the rest of the American Union.
Coronaviruses are enveloped viruses with a positive polarity RNA genome belonging to the coronaviridae family and the order Nidovirales. These viruses are widely distributed in humans and other mammals. SARS-CoV-2 has a genome of about 30,000 nucleotides and consists of four genes for the characteristic structural proteins of coronaviruses that are designated by the letters S (glycoprotein homotrimer whose distal widening of its folds forms the tips of the surface), E (small envelope protein), M (matrix protein linking the envelope to the viral core) and N (nucleocapsid phosphoprotein), in addition to ORFs (open reading frames), which encode nonstructural proteins, including enzymes that appear during its intrahospedial reproductive cycle. The size of SARS-CoV-2 virions is approximately 50-200 nm in diameter. The complete genomic sequence of this new agent is available and different qualitative and quantitative detection protocols have been developed to understand the pathophysiology of the disease.
Although most human infections are mild, epidemics of the two beta coronaviruses, severe acute respiratory syndrome (SARS-CoV) and the Middle East respiratory syndrome (MERS-CoV), caused more than 10,000 cumulative cases in the past two decades, with the lethality of 10% for SARS-CoV and 37% for MERS-CoV. The coronaviruses that have been identified to date may represent only the tip of the iceberg, with potential new and severe zoonotic events yet to occur.
The immune response with which the human being defends himself is both humoral, forming antibodies, and cellular, mediated by lymphocytes. In patients with advanced disease with respiratory failure and multiple organ failure, it has been found that they are suffering from a cytosine storm, and in fact, some treatments in these advanced cases are based on using monoclonal antibodies against cytosines.
Diagnostic methods are mainly molecular: PCR (polymerase Chain Reaction), which detects the genes of the virus E gene for screening and RdRp gene for confirmation, which is not only specific, it is also very sensitive if the sample is taken properly, and methods based on the detection of IgG (past infection) and IgM (active infection) antibodies, These are marketed as rapid tests, because of the duration of the procedure, but it does not mean an immediate diagnosis, since they will be positive until after a week after the onset of symptoms, which makes them insensitive, giving false negatives if taken in the first days of symptoms.
From the clinical point of view, in the beginning, only respiratory symptoms, fever, and general malaise were mentioned, and it was erroneously thought that 1% were asymptomatic, when in fact 35 to 40% of people have no symptoms and these help the spread of the virus by not being detected if the corresponding studies are not carried out. Fortunately, in 80% of those who present symptoms, the disease is self-limiting, but 15% require hospitalization and 5 to 6% require intensive care units for mechanical ventilation and comprehensive management of critically ill patients.
The clinical spectrum also includes alterations in the nervous system, such as cerebral and heart infarcts, producing carditis and arrhythmias; in the skin, vesicular lesions in the extremities; in the kidneys, 15% of hospitalized patients develop kidney failure and in a fraction of these the damage is permanent, requiring hemodialysis; there is also loss of smell, disseminated intravascular coagulation and a whole clinical spectrum yet to be defined. In the pediatric population, which until recently was considered immune or with little impact, a syndrome similar to Kawasaki disease is now recognized, which is severe and requires hospitalization and has even caused some deaths.
The treatment consists not only of an antiviral drug, but also of integral management of each case since it is necessary to hydrate with serum and electrolytes, medication with vasopressors for those with low blood pressure, anticoagulants, and mechanical ventilatory assistance for the subgroup that can no longer breathe on their own, that is why even if there is no effective antiviral, patients can survive if they receive adequate care, and the earlier the patient goes to the hospital, the better their prognosis. So far there is no effective and safe antiviral treatment.
One of the most promising, according to recently published studies, is remdesivir, and one of the most used initially, which studies have shown to be not only ineffective but also dangerous, due to side effects, is hydroxychloroquine, with or without azithromycin, therefore it is not recommended. The use of plasma from people who have overcome the disease has also been tried; the first studies did not show a decrease in mortality, apparently because it was administered in very advanced stages, but now attempts are being made to administer it in earlier stages.
Among the measures that have proven to be effective in controlling the spread of the virus are social distancing, in which people are asked to stay at home so that the virus does not find susceptible people and does not massively saturate hospitals, as has already occurred in Italy, Spain and New York; also effective are the use of protective masks, frequent hand washing and avoiding sneezing or coughing in front of other people.
However, for social distancing to be effective, it must be implemented early, as its effectiveness diminishes considerably if it is deferred for one or two weeks. Unfortunately, what has been achieved is threatened by an early opening of isolation due to economic and political pressures, without taking adequate precautions such as having sufficient tests and personnel for contact tracing with the possibility of having outbreaks that would force a new, stricter isolation, which would result in greater economic and social damage.
The purpose of a vaccine is to "train" a person's immune system to generate a response to fight the virus and prevent disease. All vaccines aim to expose the body to an antigen that will not cause disease but will elicit an immune response that can block or kill the virus if a person becomes infected. Conventional approaches used to do this usually focus on the use of live attenuated viruses or inactivated or fragmented viruses. At least eight types are being tested against coronavirus, which are based on different viruses or viral parts. Although multiple candidate vaccines are still in different stages of development.
Vaccine mRNA-1273-Moderna Therapeutics (United States): this vaccine involves molecular biology strategies. It is based on a messenger RNA that will produce an antibody response against the surface protein (S).
Vaccine INO-4800-Inovio Pharmaceuticals (United States): involves a design of direct injection of DNA through a plasmid (a small genetic structure) so that the patient's cells produce antibodies to fight infection.
AD5-nCoV vaccine-CanSino Biologics (China): This vaccine uses a non-replicating version of adenovirus as a vector. It carries the S protein gene (spike) from the surface of the coronavirus, which is intended to elicit the immune response to fight infection.
LV-SMENP-DC vaccine from the Geno-Immune Medical Institute in Shenzhen (China): an approach focused on the use of dendritic cells modified with lentiviral vectors.
Inactivated virus vaccine (China): this type of vaccine requires producing virus particles in reactors and then purifying them so that they lose their ability to cause disease. It uses common classical technology and is the most experienced production platform in vaccine production.
ChAdOx1 vaccine (United Kingdom): recombinant vaccine using as a vector an attenuated version of a chimpanzee adenovirus that has been modified so that it does not reproduce in humans.
We are facing a new highly transmissible virus, with a negative impact on social, economic, and educational aspects, as well as on the daily lives of people to a greater or lesser extent in different countries. Thousands of priceless lives have been lost, and although it is not yet under control, there are thousands of health workers attending the population with great intensity in this crisis. The scientific community is providing therapeutic options while searching for an effective vaccine; however, its control requires the collaboration of society in maintaining the social distance; for, without this participation, we will lose what has been gained through the efforts of thousands of people.